# Malaria: Relative Bioavailability and Food Effect of DSM265

> **NCT03637517** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** DSM265-TPGS 34% SDD, 400 mg fasted
- **DRUG:** DSM265-TPGS 34% SDD, 400 mg fed
- **DRUG:** DSM265 25% SDD, 400 mg fasted

## Key facts

- **NCT ID:** NCT03637517
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-03
- **Primary completion:** 2018-11-19
- **Final completion:** 2018-11-19
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03637517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03637517, "Malaria: Relative Bioavailability and Food Effect of DSM265". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03637517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*